Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MiMedx Group, Inc. before investing.

In this article, we go over a few key elements for understanding MiMedx Group, Inc.’s stock price such as:

• MiMedx Group, Inc.’s current stock price and volume
• Why MiMedx Group, Inc.’s stock price changed recently
• Upgrades and downgrades for MDXG from analysts
• MDXG’s stock price momentum as measured by its relative strength

About MiMedx Group, Inc. (MDXG)

Before we jump into MiMedx Group, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Want to learn more about MiMedx Group, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MiMedx Group, Inc..

MiMedx Group, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 10:32 AM, CST, MiMedx Group, Inc.’s stock price was $3.665.

MiMedx Group, Inc. is down 0.68% from its previous closing price of $3.690.

During the last market session, MiMedx Group, Inc.’s stock traded between $3.610 and $3.730. Currently, there are approximately 148.45 million shares outstanding for MiMedx Group, Inc..

MiMedx Group, Inc.’s price-earnings (P/E) ratio is currently at 18.4, which is low compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

MiMedx Group, Inc. Stock Price History

MiMedx Group, Inc.’s (MDXG) price is currently up 9.08% so far this month.

During the month of May, MiMedx Group, Inc.’s stock price has reached a high of $3.730 and a low of $3.385.

Over the last year, MiMedx Group, Inc. has hit prices as high as $7.990 and as low as $3.025. Year to date, MiMedx Group, Inc.’s stock is down 45.86%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MiMedx Group, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 07, 2026,, no analysts have changed their rating of MiMedx Group, Inc.’s stock over the last month.

Additionally, you'll want to evaluate MiMedx Group, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MiMedx Group, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

MiMedx Group, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MiMedx Group, Inc. (MDXG) by visiting AAII Stock Evaluator.

Relative Price Strength of MiMedx Group, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, MiMedx Group, Inc. has a weighted four-quarter relative price strength of -21.30%, which translates to a Momentum Score of 9 and is considered to be Very Weak.

Want to learn more about how MiMedx Group, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MiMedx Group, Inc. Stock Price: Bottom Line

As of May 8, 2026, MiMedx Group, Inc.’s stock price is $3.665, which is down 0.68% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MiMedx Group, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.